1. Bauerfeind P, Blum AL (editors), and 57 co-authors: Ulkusalmanach 1 + 2. Zweite, erweiterte Auflage. Berlin, Springer-Verlag, 1990. This is probably the most comprehensive recent compilation of data on peptic ulcer disease. It includes critical reviews on current topics and an analysis of 1735 original publications. Unfortunately, the 835-page volume is available in German only.
2. Alexander-Williams J: A requiem for vagotomy. Despite the last efforts of surgeons. Br Med J
302:547–548, 1991. In view of the efficacy of current antiulcer drugs and eradication therapy of H pylori, one of the major protagonists of vagotomy for peptic ulcer fails to see any further role for vagotomy in peptic ulcer disease.
3. Lanas A, Sekar MC, Hirschowitz BI: Objective evidence of aspirin use in both ulcer and nonulcer upper and lower gastrointestinal bleeding. Gastroenterology
103:862–869, 1992. Measurement of platelet cyclooxygenase activity in gastrointestinal bleeding reveals that 80% of the patients were currently taking aspirin. 21.5% of the patients were not aware of, or did not admit, current aspirin consumption.
4. Koelz HR: Antisecretory versus protective drugs, in Halter F, Garner A, Tytgat GNJ (eds): Mechanisms of Peptic Ulcer Healing. Dordrecht, Kluwer Academic Publishers, 1991, pp 231–242. The two major groups of antiulcer drugs are reviewed, in particular also with respect to potential advantages of sucralfate in smokers.
5. Behar J, Roufail W, Thomas E, et al: Efficacy of sucralfate in the prevention of recurrence of duodenal ulcers. J Clin Gastroenterol
9(suppl 1):23–30, 1987. Placebo-controlled, double-blind randomized study in duodenal ulcer patients demonstrating clear superiority of sucralfate.